% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Eimeren:910743,
      author       = {Eimeren, Thilo and Antonini, Angelo and Berg, Daniela and
                      Bohnen, Nico and Ceravolo, Roberto and Drzezga, Alexander
                      and Höglinger, Günter U. and Higuchi, Makoto and Lehericy,
                      Stephane and Lewis, Simon and Monchi, Oury and Nestor, Peter
                      and Ondrus, Matej and Pavese, Nicola and Peralta, María
                      Cecilia and Piccini, Paola and Pineda-Pardo, José Ángel
                      and Rektorová, Irena and Rodríguez-Oroz, María and
                      Rominger, Axel and Seppi, Klaus and Stoessl, A. Jon and
                      Tessitore, Alessandro and Thobois, Stephane and Kaasinen,
                      Valtteri and Wenning, Gregor and Siebner, Hartwig R. and
                      Strafella, Antonio P. and Rowe, James B.},
      title        = {{N}euroimaging biomarkers for clinical trials in atypical
                      parkinsonian disorders: {P}roposal for a {N}euroimaging
                      {B}iomarker {U}tility {S}ystem},
      journal      = {Alzheimer's $\&$ dementia / Diagnosis, assessment $\&$
                      disease monitoring},
      volume       = {11},
      number       = {1},
      issn         = {2352-8729},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {FZJ-2022-04113},
      pages        = {301 - 309},
      year         = {2019},
      abstract     = {IntroductionTherapeutic strategies targeting protein
                      aggregations are ready for clinical trials in atypical
                      parkinsonian disorders. Therefore, there is an urgent need
                      for neuroimaging biomarkers to help with the early detection
                      of neurodegenerative processes, the early differentiation of
                      the underlying pathology, and the objective assessment of
                      disease progression. However, there currently is not yet a
                      consensus in the field on how to describe utility of
                      biomarkers for clinical trials in atypical parkinsonian
                      disorders.MethodsTo promote standardized use of neuroimaging
                      biomarkers for clinical trials, we aimed to develop a
                      conceptual framework to characterize in more detail the kind
                      of neuroimaging biomarkers needed in atypical parkinsonian
                      disorders, identify the current challenges in ascribing
                      utility of these biomarkers, and propose criteria for a
                      system that may guide future studies.ResultsAs a consensus
                      outcome, we describe the main challenges in ascribing
                      utility of neuroimaging biomarkers in atypical parkinsonian
                      disorders, and we propose a conceptual framework that
                      includes a graded system for the description of utility of a
                      specific neuroimaging measure. We included separate
                      categories for the ability to accurately identify an
                      intention-to-treat patient population early in the disease
                      (Early), to accurately detect a specific underlying
                      pathology (Specific), and the ability to monitor disease
                      progression (Progression).DiscussionWe suggest that the
                      advancement of standardized neuroimaging in the field of
                      atypical parkinsonian disorders will be furthered by a
                      well-defined reference frame for the utility of biomarkers.
                      The proposed utility system allows a detailed and graded
                      description of the respective strengths of neuroimaging
                      biomarkers in the currently most relevant areas of
                      application in clinical trials.Keywords: Biomarker, Trials,
                      PSP, MSA, CBD, CBS, Neurodegeneration, Biomarker,
                      Multicentric, Multisite, Neuroimaging, Harmonization, PET,
                      MRI},
      cin          = {INM-2},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-2-20090406},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {30984816},
      UT           = {WOS:000723892800035},
      doi          = {10.1016/j.dadm.2019.01.011},
      url          = {https://juser.fz-juelich.de/record/910743},
}